{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T03:13:33Z","timestamp":1788491613159,"version":"build-2803163510"},"reference-count":10,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JOP"],"published-print":{"date-parts":[[2005,5]]},"abstract":"Purpose<\/jats:title> Most chemotherapy (CT) administration occurs in routine care settings, yet little is known about treatment-related toxicity outside of clinical trials. To examine trends in toxicity, modify practice, and establish benchmarks for severe toxicity in a community cancer center we created a prospective registry of all treatment-related hospitalizations at the North Shore Medical Center Cancer Center, a community-based cancer facility in Peabody, MA. <\/jats:p><\/jats:sec>Methods<\/jats:title> Eligible population consisted of all adult cancer patients admitted to the hospital within 30 days of their last CT administration. Each admission was reviewed by a panel of hospital staff to determine whether admission was treatment-related. Information on admission was collected using a standard form. <\/jats:p><\/jats:sec>Results<\/jats:title> Between October 2001 and December 2003, there were 365 hospitalizations among patients receiving CT, 117 (32%) of which were deemed treatment-related. The median age of the cohort with treatment-related toxicity was 67 years, and 41% were male. Most frequent diagnoses were non-Hodgkin's lymphoma (23%) and colorectal cancer (21%), with 49% of the patients receiving treatment with palliative intent. The most common reasons for admission were gastrointestinal toxicity or infection. The mean length of stay was 7.1 days. Seven patients (6%) died during hospitalization. When the registry was reviewed to identify areas where care may be improved, several admissions for decadron-related hyperglycemia in nondiabetic patients with myeloma were noted. This led to introduction of glucose monitoring guidelines with no subsequent admissions for this toxicity since then. <\/jats:p><\/jats:sec>Conclusions<\/jats:title> About one third of hospital admissions in patients receiving CT are treatment-related and most occur in patients with advanced disease. Collection of data on toxicity in the routine care setting is feasible and may facilitate quality improvement. <\/jats:p><\/jats:sec>","DOI":"10.1200\/jop.2005.1.1.15","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T11:42:21Z","timestamp":1487936541000},"page":"15-19","source":"Crossref","is-referenced-by-count":18,"title":["Development of a Patient Registry to Evaluate Hospital Admissions Related to Chemotherapy Toxicity in a Community Cancer Center"],"prefix":"10.1200","volume":"1","author":[{"given":"Monika K.","family":"Krzyzanowska","sequence":"first","affiliation":[{"name":"Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA; and North Shore Medical Center Cancer Center, Peabody, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Treacy","sequence":"additional","affiliation":[{"name":"Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA; and North Shore Medical Center Cancer Center, Peabody, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betty","family":"Maloney","sequence":"additional","affiliation":[{"name":"Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA; and North Shore Medical Center Cancer Center, Peabody, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoinette","family":"Lavino","sequence":"additional","affiliation":[{"name":"Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA; and North Shore Medical Center Cancer Center, Peabody, MA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph O.","family":"Jacobson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/canjclin.54.1.8"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1046\/j.1524-4733.2002.51083.x"},{"key":"B4","first-page":"14S","volume":"23","author":"Dranitsaris G","year":"2004","journal-title":"Proc Am Soc Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040135"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.09.087"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.06.020"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.05.088"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1097\/00005650-200208001-00009"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.300.6737.1458"}],"container-title":["Journal of Oncology Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/jop.2005.1.1.15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T22:16:49Z","timestamp":1653517009000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/jop.2005.1.1.15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":10,"aliases":["10.1200\/jop.1.1.15"],"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["10.1200\/jop.2005.1.1.15"],"URL":"https:\/\/doi.org\/10.1200\/jop.2005.1.1.15","relation":{},"ISSN":["1554-7477","1935-469X"],"issn-type":[{"value":"1554-7477","type":"print"},{"value":"1935-469X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}